1. Background {#sec1}
=============

Human immunodeficiency virus (HIV) infection is a risk factor for cancer \[[@r1], [@r2]\]. HIV-associated cancers can be divided into acquired immune deficiency syndrome (AIDS)-defining cancers (ADC) and non-AIDS-defining cancers (NADC) \[[@r2]\]. The availability of effective antiretroviral therapy (ART) has lowered the incidence of cancer but there has been a simultaneous increase in the life expectancy of people living with HIV \[[@r3]\]. Consequently, the overall incidence of cancer and AIDS-defining cancer has stabilized over the last two decades (except invasive cervical cancer), while there has been an absolute increase in NADC \[[@r2]-[@r6]\]. HIV-associated cancer is one of the leading causes of death in HIV patients \[[@r7]-[@r9]\].

ADC include non-Hodgkin's lymphoma (NHL), invasive cervical carcinoma, and Kaposi's sarcoma (KS) \[[@r10]\]. NADC include lung cancer, anal cancer, Hodgkin's lymphoma, *etc.* The standardized incidence ratio (which compares the cancer rate in patients with HIV to the expected rate in the general population) \[[@r11]\] varies from 2 in lung cancer to 498 in Kaposi's sarcoma. NHL remains the most common cancer in patients with HIV worldwide \[[@r2], [@r12]\].

Risk factors for cancer in HIV include immunosuppression, oncogenic potential of HIV \[[@r13]\], co-infection with other oncogenic virus such as hepatitis B and C \[[@r13]\], human herpes virus-8 (HHV-8) infection \[[@r14], [@r15]\], human papilloma virus (HPV) \[[@r16]\], Epstein-Barr virus (EBV) \[[@r17], [@r18]\], *etc.* HIV can also sensitize the cells to the oncogenic potential of tobacco, as suggested by an increase in the risk of lung cancer in people living with HIV (three times the general population) after adjustment for smoking status \[[@r13]\].

In 2016, there were 36.7 million people living with HIV worldwide; 2.1 million of these lived in India \[[@r19], [@r20]\]. Based on regional records, NHL is the most common cancer overall \[[@r21]-[@r24]\] and Kaposi's sarcoma is rare \[[@r23]\]. Increasing access to ART \[[@r25]\] is expected to decrease the overall incidence of cancer in this population, but the spectrum of cancer in people living with HIV in India needs to be better understood for effective screening.

We aim to look at the prevalence and spectrum of cancer in HIV patients at a tertiary care referral center in North India.

2. Methods {#sec2}
==========

From July 2013 to June 2016, we used a structured history and physical examination to screen successive adult (≥18 years) HIV-positive patients, irrespective of whether or not on any anti-retroviral therapy (ART), who presented at the ART center at the hospital for malignancy. The institute's ethics committee approved the protocol. Written informed consent was obtained from all the participants prior to their participation in the study.

Baseline demographic data were recorded regarding education, occupation, marital status, status of spouse and children, and likely mode of transmission. CD4 count was assessed for all the patients with HIV and cancer at the ART center. CD4 cell counts were measured by flow cytometry using BD FACS CALIBUR and fluorescein monoclonal antibodies (Becton Dickenson Biosciences, San Jose, CA, USA).

We assessed for known risk factors for malignancies such as current or former smoking, tobacco chewing, and alcohol intake. Those suspicious for malignancy were further evaluated with radiological investigations such as X-ray, ultrasound, computed tomography (CT) scan, magnetic resonance imaging (MRI), and positron-emission tomography (PET)-CT scan of the region of interest. All the malignancies were confirmed by histopathological examination. The time since the diagnosis of HIV and malignancy was recorded for all the patients. The overall prevalence of malignancy in HIV was calculated.

All the consecutive patients who presented at the cancer center with a confirmed diagnosis of a malignancy were screened for HIV antibodies using ELISA. All patients, irrespective of type and stage of malignancy were included in the study after due consent. Biopsy reports of all the patients diagnosed elsewhere were reviewed at this hospital for confirmation of diagnosis. The patients who tested positive for HIV were referred to the ART clinic at the All India Institutes of Medical Sciences (AIIMS) for HIV treatment and follow-up.

The study was continued till 1000 patients each were recruited at the ART center and the cancer center respectively.

All the patients with HIV and cancer were followed-up for treatment response and outcome for one year post-enrollment.

The data were recorded in a predesigned Excel spreadsheet. All the participants were given a unique code number. We calculated the prevalence of cancer in the HIV patients and the prevalence of HIV infection in patients with cancer over the three-year period. The descriptive statistics were calculated, including means and standard deviations for the continuous variables and percentages for the categorical variables. One-way ANOVA with Bonferroni's correction was used to find significant differences in the data following parametric distribution, while the Wilcoxon rank-sum test was used to find differences in CD4 counts between the groups.

3. Results {#sec3}
==========

There were 999 HIV-positive patients enrolled from the ART clinic and 998 patients from the cancer clinic. Most of the patients at the ART center were males, whereas most patients at the cancer center were females.

Of the 999 HIV-positive patients, 20 patients were diagnosed with a malignancy.

The overall prevalence of cancer in the HIV patients was 2% (20/999) \[95% confidence interval (CI)I 1.13, 2.87\].

Of the 998 cancer patients, 9 patients had HIV infection. The overall prevalence of HIV in the cancer patients was 0.9% (9/998) (95% CI 0.31, 1.49). For the analysis, we divided the patient population into three groups: HIV only (group 1, n=979), cancer only (group 2, n=989), and HIV and cancer (group 3, n=29) (Table **[1](#T1){ref-type="table"}**).

Most of the patients in the three groups did not smoke or consume significant amounts of alcohol. The patients with HIV and cancer were older than those with HIV only (44.8±10.5 *vs* 36.7±9.2 years, p-value \<0.05).

Almost half of the patients with HIV and cancer had fever, involuntary weight loss, and loss of appetite in the preceding six months, while only one-third of the patients in the HIV only group had these symptoms. There was no significant difference in the CD4 counts in groups 1 and 3 at the time of diagnosis of cancer (median CD4 count 246 vs 188, p-value \>0.05).

Among the patients with HIV and cancer (n=29), 22 were male and 7 were female. Overall, 19 patients had AIDS-defining cancers while 10 had non-AIDS-defining cancers. The most common malignancy was non-Hodgkin's lymphoma (13/29) followed by invasive cervical carcinoma (6/29). No case of KS was observed.

There was only one case of hepatitis B co-infection in patients with HIV and cancer. At one-year follow up, 19 patients were alive, 8 patients had died, and 2 patients could not be traced.

4. Discussion {#sec4}
=============

Our study suggests that approximately 2% of HIV patients had cancer, while 1% of cancer patients had HIV infection. AIDS-defining cancers remain more common than non-AIDS-defining cancers. In more developed countries with a higher life expectancy, non-AIDS-defining cancers predominate. It is expected that better coverage of ART, control of communicable diseases, and increased longevity would lead to an increase in non-AIDS-defining cancers and a decrease in AIDS-defining cancers \[[@r2], [@r26], [@r27]\].

The prevalence of HIV infection in cancer patients is very low, but it is approximately four times the national population (the national prevalence of HIV infection in India is 0.26%) \[[@r28]\]. In a similar report from Maharashtra, India, 3,832 patients were studied and the prevalence of HIV infection was only 1.2% \[[@r29]\].

AIDS-defining cancer such as NHL was around four times more common in patients with HIV compared to HIV-negative cancer patients. At the same center as the present study (AIIMS), a retrospective study analyzing malignancy in HIV patients during the initial years of ART (2005-2013) suggested a similar infrequent occurrence of malignancy in HIV, with NHL being the most common \[[@r30]\]. Most regional studies from India concur that NHL is the most common malignancy in HIV and KS is very rare \[[@r21]-[@r23], [@r29]-[@r33]\]. One of the reasons postulated is the low seroprevalence of HHV-8 in the Indian population \[[@r34]\]. However, a recent study by Munawwar *et al.* reported that 26% of 165 HIV-positive ART-naïve Indian men (90% heterosexual) had antibodies against HHV-8 \[[@r35]\]. The role of factors additional to HHV-8 in the pathogenesis of KS needs to be explored.

Diffuse large B-cell lymphoma is the most common subtype of NHL overall as well in the HIV population \[[@r2], [@r23], [@r24]\]. While EBV is commonly associated with immunodeficiency-related Hodgkin's lymphoma, its role in the pathogenesis of NHL in HIV varies, with most cases of primary CNS lymphoma expressing EBV proteins while rarely being associated with Burkitt lymphoma \[[@r36]-[@r38]\]. Outcomes of lymphoma have been worse in HIV-positive patients \[[@r39]-[@r41]\]. With effective chemotherapy and ART, there has been a better outcome reported with some studies showing similar outcomes as in HIV-negative patients \[[@r39], [@r42]-[@r44]\].

Patients with HIV are susceptible to chronic infection by oncogenic strains of HPV. In addition to causing cervical cancer, HPV also causes anal cancers and head and neck cancers \[[@r2], [@r45]\]. There is a high prevalence of HPV infection in HIV-infected women; almost one in four such patients have HPV co-infection with a high rate of intraepithelial neoplasia \[[@r46]\].

In this study, we observed a low prevalence of malignancies at the time of HIV diagnosis. We screened many successive patients at the ART and cancer center. It is yet to be observed whether HIV positive patients with malignancies have similar outcome as seronegative patients of the same stage. Drug interactions among chemotherapeutic agents and ART are also largely unknown. Though we followed HIV-cancer patients for one-year post-enrollment, stage of the diagnosed malignancy, treatment given and response is unknown. With effective ART and improvement in immunity it is expected that incidence of malignancy will be reduced, follow-up studies will help understand natural history of this disease.

HIV-related cancers are preventable through vaccination and early and highly active ART \[[@r2], [@r47], [@r48]\]. Screening of all HIV patients with clinical and radiological examinations should be conducted for early diagnosis and treatment of cancer. With this study, we have created a national HIV-cancer registry that will help to understand the spectrum of HIV-related malignancy in the hospital and community-based setting.

Conclusion
==========

There is a low prevalence of cancer at the time of HIV diagnosis in North India. Similarly, HIV infection is rare in cancer patients. AIDS defining cancers remain most prevalent, while Kaposi's sarcoma is rare. Follow-up of these patients is required to see whether these patients have similar outcomes as compared to seronegative patients of the same stage.
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Demographic variables, risk factors and malignancy distribution.

  -----------------------------------------------------------------------------------------
      **Variables**                **HIV Only**\   **Cancer Only**\   **HIV and Cancer**\
                                   **n=979**       **n=989**          **n=29**
  -------------------------------- --------------- ------------------ ---------------------
       Age (years)                 36.7±9.2        48.5±13.7          44.8±10.5

       Male (%)                    740 (75.5%)     361 (36.5%)        22 (75.8%)

       CD4 (cells/mm^3^)           246 (155,377)                      188 (101,411)

       **Marital status**                                             

  • Married                        361 (37%)       909 (92%)          25 (93%)

  • Unmarried                      618 (63%)       80 (8%)            4 (7%)

       **Transmission route**                                         

  • Heterosexual                   902 (92%)       \-                 21 (72.4%)

  • Mother to child transmission   15 (1.5%)                          \-

  • Other                          62 (6.3%)                          8 (27.6%)

       **Smoking**                                                    

  • Current smoker                 47 (5%)         6 (0.6%)           3 (10.3%)

  • Past smoker                    187 (19%)       43 (4.3%)          8 (27.5%)

  • Never smoked                   745 (76%)       942 (95%)          18 (62%)

       **Alcohol consumption**                                        

  • Habitual drinker               723 (73.8%)     976 (98.6%)        20 (69%)

  • Non-Alcoholic                  256 (26.2%)     13 (1.4%)          9 (31%)

       **Substance abuse**                                            

  • Current or past                8 (0.8%)        2 (0.2%)           3 (10.4%)

  • Never                          971 (99.2)      987 (99.8%)        26 (89.6%)

       **Fever**                   340 (34.7%)     65 (6.6%)          15 (51.2%)

       **Weight Loss**             386 (39.3%)     272 (27.5%         15 (51.2%)

       **Loss of appetite**        333 (34%)       269 (27.2%)        15 (51.2%

       **Lymphadenopathy**         152 (15.5%)     237 (24%)          8 (27.6%)

       **Malignancy type**                                            

  • Non-Hodgkin's lymphoma                         121 (12.4%)        13 (44.8%)

  • Carcinoma Cervix                               147 (15%)          6 (20.7%)

  • Hodgkin's lymphoma                             37 (3.4%)          4 (13.8%)

  • Carcinoma Lung                                 41 (4.2%)          1 (3.4%)

  • Carcinoma Gall bladder                         24 (2.4%)          1 (3.4%)

  • Sino-nasal SCC                                 15 (1.5%)          1 (3.4%)

  • Skin SCC                                       2 (0.2%)           1 (3.4%)

  • Adenocarcinoma Colon                           31 (3.1%)          2 (6.8%)
  -----------------------------------------------------------------------------------------

Data is presented as mean ± standard deviation, Mean (Inter-quartile range); SCC: Squamous cell carcinoma
